

AMENDMENTS

In the Specification:

The Specification has been amended as suggested by the Office to add the word "Brief" to the title "Description of Drawings" on page 7; and to delete the lines 6 through 10 on page 1. Please see Appendix A for the marked pages.

In the Claims:

Claims 1-4, 7, 14, 15, and 19 remain in the application. Claims 1-4, 7 and 19 have been amended. Please see the Complete Listing of the Claims in Appendix B.

Claims 1, 4 and 7 have been amended to recite that these products are "isolated," as recommended by the Office. This amendment is for clarification only and is not intended to narrow the scope of the claims. Support for this addition is found, for example, in the Specification, pg. 6, line 11, to pg. 7, line 6; pg. 8, lines 14-24, the Abstract, and in claims 1, 4, and 7 as originally filed.

Claims 2, 3, and 7 have been amended to number the nucleotide bases as in SEQ ID NO:1, and not as in Figure 1, as suggested by the Office. Support for these amendments are found, for example, in the Specification at Fig. 1-1 and Sequence Listing of SEQ ID NO:1, and in Claims 2, 3, and 7 as originally filed.

Claims 1, 2, and 3 have been amended to clarify that the new isolated hGR 1Ap/e is an isolated "sequence." Support for this amendment is found, for example, in the Specification, pg. 6, line 11, to pg. 7, line 6; pg. 8, lines 14-24, the Abstract, and in claims 1, 2, and 3 as originally filed.

Claim 19 has been amended to depend from Claim 1. Support for this amendment is found, for example, in Claims 1 and 19 as originally filed.